Pernix Therapeutics Competitors and Similar CompaniesClear all
Pernix Therapeutics's competitors and similar companies include Moderna, Alnylam, Celyad and Sorrento Therapeutics.
 Pernix Therapeutics Pernix Therapeutics is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products primarily for the pediatric market. |  Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| |
Founding Date | Founding Date N/A | Founding Date 2010 | Founding Date 2002 | Founding Date 2007 | Founding Date 2006 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Morristown, US HQ | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations San Diego, US HQ San Diego, US | ||
Employees | Employees 171 | Employees 5,8004% increase | Employees 1,32324% increase | Employees 17 | Employees 31019% decrease |
Valuation ($) | Valuation ($) 3 m | Valuation ($) 21.2 b | Valuation ($) 36.5 b | Valuation ($) 11.8 m | Valuation ($) 1.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $146.1m (FY, 2017) | Revenue (est.) $1.9b (FY, 2025) | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) €21k (FY, 2025) | Revenue (est.) $62.8m (FY, 2022) |
Cost of goods | Cost of goods $44.6m (FY, 2017) | Cost of goods $868m (FY, 2025) | Cost of goods $677.2m (FY, 2025) | Cost of goods €8k (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $101.4m (FY, 2017) | Gross profit $1.1b (FY, 2025) | Gross profit $3b (FY, 2025) | Gross profit €5.9m (FY, 2025) | Gross profit N/A |
Net income | Net income ($77.1m) (FY, 2017) | Net income ($2.8b) (FY, 2025) | Net income $313.7m (FY, 2025) | Net income €830k (FY, 2025) | Net income ($577.8m) (FY, 2022) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 1.8b | Total funding raised $ 1.5b | Total funding raised N/A | Total funding raised $ 42.6m |
For sources of this data, please see the company profile
View Company Profiles
Moderna
HQ
Cambridge, US
Employees
5,800↑ 4% increase
Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companyCelyad
HQ
Mont-Saint-Guibert, BE
Employees
17
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View company